2021 has been good for the stock markets so far, which have run-up quite a bit despite some fluctuations. As a result, some of the FTSE 100 stocks I like best, have also seen a significant rise in their share prices. In fact, they have now increased so much, that they are on my list of stocks to buy if there were a market crash tomorrow.
This does not mean that I have a pessimistic outlook on the stock markets. Only that I like to be prepared for a seemingly challenging situation, if it were to arrive. As it happens, some of the stocks I like best right now are also among the priciest ones around.
5 Stocks For Trying To Build Wealth After 50
Markets around the world are reeling from the coronavirus pandemic… and with so many great companies trading at what look to be ‘discount-bin’ prices, now could be the time for savvy investors to snap up some potential bargains.
But whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times.
Fortunately, The Motley Fool UK analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global upheaval…
We’re sharing the names in a special FREE investing report that you can download today. And if you’re 50 or over, we believe these stocks could be a great fit for any well-diversified portfolio.
Spirax-Sarco Engineering is the priciest FTSE 100 stock
The first of these is the FTSE 100 engineering giant Spirax-Sarco Engineering (LSE: SPX). It is the most pricey stock among the index’s constituents. As I write, its share price is at a huge £162.6. It also has an enviable share price trajectory over time. In the past year, it has risen over 40%. And in the last three years, it has seen an almost 160% increase!
Its share price has dipped a bit since yesterday, after it released its trading update. Because of supply chain disruptions and rising costs, the company has reduced its forecast for both 2021 and 2022. While this explains the softening in its price, I would be very surprised if it continues to hold the stock down. The company still expects “record levels of revenue, profit, and operating margin for the full year 2021”.
It is little wonder then that its price-to-earnings (P/E) is at a huge 58 times right now. This shows the kind of premium investors place on the financially robust company. But because it looks a little too high to me, I would ideally wait for a market crash before buying the stock.
AstraZeneca goes from strength-to-strength
I might have missed the opportunity to buy Spirax-Sarco Engineering earlier, when it was still cheap, but I did buy another pricey stock. I am talking about the pharmaceuticals biggie AstraZeneca (LSE: AZN). The Anglo-Swedish company made its name as a cancer treatment specialist. But its popularity rose to a whole new level last year when it developed a Covid-19 vaccine with the University of Oxford.
With its current share price at £84, it is the fifth most pricey FTSE 100 stock right now. There are huge variations in its P/E estimates across five different sources I checked. The lowest is around 45 times and the highest a huge 100 times. The point here is this:whichever way I look at the stock, it is priced at at least 45 times its earnings, if not much more.
But then, it has always been the case for AstraZeneca. In the past year, its share price has fluctuated a lot, resulting in almost no gains in the past year. But that would not stop me from buying more of the robust stock for the long term if a stock market crash were to happen. Over the past five years, it has doubled its share price. That, for me, is reason alone to consider buying more of it.
FREE REPORT: Why this £5 stock could be set to surge
Are you on the lookout for UK growth stocks?
If so, get this FREE no-strings report now.
While it’s available: you’ll discover what we think is a top growth stock for the decade ahead.
And the performance of this company really is stunning.
In 2019, it returned £150million to shareholders through buybacks and dividends.
We believe its financial position is about as solid as anything we’ve seen.
- Since 2016, annual revenues increased 31%
- In March 2020, one of its senior directors LOADED UP on 25,000 shares – a position worth £90,259
- Operating cash flow is up 47%. (Even its operating margins are rising every year!)
Quite simply, we believe it’s a fantastic Foolish growth pick.
What’s more, it deserves your attention today.
So please don’t wait another moment.
Get the full details on this £5 stock now – while your report is free.
Manika Premsingh owns shares of AstraZeneca. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.
This post was originally published on Motley Fool